VAXART (VXRT)
(Delayed Data from NSDQ)
$0.94 USD
+0.03 (2.99%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $0.94 0.00 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
VXRT 0.94 +0.03(2.99%)
Will VXRT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VXRT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VXRT
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
VXRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
Other News for VXRT
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart reports inducement grants under Nasdaq listing rule
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
Vaxart: Vaccine platform may be effective for HPV-related cervical dysplasia
Vaxart’s Promising Vaccine Pipeline: Leading in Mucosal Immunity with Government Support and Competitive Advantages